Randomized, Double-blind, Placebo-controlled, Positive Controlled, 3-period, 6-sequence, Crossover Study to Define the Electrocardiogram Effects of a Single Dose of Telotristat Etiprate (LX1606) 1500 mg Compared With Placebo and Open Label Moxifloxacin in Healthy Subjects: A Thorough QT Study
Phase of Trial: Phase I
Latest Information Update: 10 Sep 2014
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome
- Focus Pharmacodynamics
- Sponsors Lexicon Pharmaceuticals
- 05 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Jun 2014 New trial record